Theratechnologies has signed another license agreement with Bioartificial Gel Technologies (B.A.G.Tech), extending the license granted in 1999 relating to its extraction process and the applications of its platelet-derived growth factor cocktail.
The license agreement announced today covers their in vivo use for therapeutic purposes in the areas of tissue engineering and wound healing.
“We are very pleased to continue our association with B.A.G.Tech with this new agreement which will enable this promising technology to be developed beyond the field of dermo-cosmetic”, said Dr. André de Villers, President and CEO of Theratechnologies.
BioArtiticial Gel Technologies operates in the biotechnology sector.
Its mission is to develop and market systems for the progressive release of active agents based on a hydrogel technological springboard.
Theratechnologies is a Canadian biopharmaceutical company engaged in the fields of therapeutic peptides and cell therapy.